KAZIA THERAPEUTICS-SPON ADR (KZIA)
US48669G1058 - ADR
KAZIA THERAPEUTICS-SPON ADR
NASDAQ:KZIA (1/3/2025, 8:00:02 PM)
After market: 1.8483 +0.05 (+2.68%)1.8
+0.05 (+3.15%)
Company Profile
Kazia Therapeutics Ltd is a AU-based company operating in Biotechnology industry. The company is headquartered in Sydney, New South Wales. Kazia Therapeutics Limited is an oncology focused drug development company. The firm is engaged in the pharmaceutical research and development. Its lead program includes Paxalisib and EVT801. Paxalisib is a small molecule inhibitor of the PI3K / Akt / mTOR pathway, a central regulator of growth and cell division that is dysregulated in many types of cancer. Paxalisib is being developed for several forms of brain cancer. EVT801 is a small molecule inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3), which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. EVT801 is an inhibitor of VEGFR3, a cellular receptor for VEGF. The Company’s drug candidates are designed to treat disease, such as brain cancer, renal cancer, and liver cancer.
Company Info
KAZIA THERAPEUTICS-SPON ADR
Three International Towers Level 24,, 300 Barangaroo Avenue
Sydney NEW SOUTH WALES 2000
P: 1161298780088
CEO: James Garner
Employees: 0
Website: https://www.kaziatherapeutics.com/
KZIA News
4 days ago - ChartmillCurious about what's happening in today's session? Check out the latest stock movements and price changes.Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
4 days ago - Yahoo FinanceWhy Is Brain Cancer-Focused Kazia Therapeutics Stock Trading Lower On Tuesday?Kazia Therapeutics Limited (NASDAQ:KZIA) stock is trading lower on Tuesday after the company provided a regulatory update on paxalisib for glioblastoma (GBM) following its Type C clinical meeting with the FDA. In July 2024, the company reported topline results from the GBM-AGILE study in which newly diagnosed unmethylated patients with glioblastoma treated with paxalisib showed a clinically meaningful improvement in a prespecified secondary analysis for overall survival (OS) compared to standard
4 days ago - ChartmillWhich stocks are experiencing notable movement on Tuesday?Top movers analysis in the middle of the day on 2024-12-31: top gainers and losers in today's session.
4 days ago - ChartmillThe market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs.There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday.
5 days ago - Kazia Therapeutics LimitedKazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today provided a regulatory update on paxalisib for...
2 months ago - Kazia Therapeutics LimitedKazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, announced that the U.S. Food and Drug Administration...
KZIA Twits
Here you can normally see the latest stock twits on KZIA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
